A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

By T. King, W. Bradford, S. Castro-Bernardini, E. Fagan, I. Glaspole, M. Glassberg, E. Gorina, P. Hopkins, D. Kardatzke, L. Lancaster and 7 more. New England Journal of Medicine, 2014

2,093 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/01a2be944dd6e4907fc1e9be2291e821ee176aab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Kirkland
2. J. Justice
3. T. Tchkonia
4. A. Nambiar
5. Nathan K. LeBrasseur
6. R. Pascual
7. S. Hashmi
8. L. Prata

Citations in the corpus

• Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019, result): “Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”